These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 22798530)

  • 1. Complement activation and cardiac surgery: a novel target for improving outcomes.
    Stahl GL; Shernan SK; Smith PK; Levy JH
    Anesth Analg; 2012 Oct; 115(4):759-71. PubMed ID: 22798530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pexelizumab and its role in the treatment of myocardial infarction and in coronary artery bypass graft surgery: a review.
    Patel JA; Ghatak SB
    Recent Pat Cardiovasc Drug Discov; 2008 Jun; 3(2):145-52. PubMed ID: 18537766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlling the complement system in inflammation.
    Kirschfink M
    Immunopharmacology; 1997 Dec; 38(1-2):51-62. PubMed ID: 9476114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying complement therapeutics to rare diseases.
    Reis ES; Mastellos DC; Yancopoulou D; Risitano AM; Ricklin D; Lambris JD
    Clin Immunol; 2015 Dec; 161(2):225-40. PubMed ID: 26341313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of complement modulation.
    Wagner E; Frank MM
    Nat Rev Drug Discov; 2010 Jan; 9(1):43-56. PubMed ID: 19960015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the lectin pathway of complement by cardiopulmonary bypass contributes to the development of systemic inflammatory response syndrome after paediatric cardiac surgery.
    Pągowska-Klimek I; Świerzko AS; Michalski M; Głowacka E; Szala-Poździej A; Sokołowska A; Moll M; Krajewski WR; Romak J; Cedzyński M
    Clin Exp Immunol; 2016 May; 184(2):257-63. PubMed ID: 26703090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C1 esterase inhibitor in pediatric cardiac surgery with cardiopulmonary bypass plays a vital role in activation of the complement system.
    Miyamoto T; Ozaki S; Inui A; Tanaka Y; Yamada Y; Matsumoto N
    Heart Vessels; 2020 Jan; 35(1):46-51. PubMed ID: 31278424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
    Shernan SK; Fitch JC; Nussmeier NA; Chen JC; Rollins SA; Mojcik CF; Malloy KJ; Todaro TG; Filloon T; Boyce SW; Gangahar DM; Goldberg M; Saidman LJ; Mangano DT;
    Ann Thorac Surg; 2004 Mar; 77(3):942-9; discussion 949-50. PubMed ID: 14992903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The possible role of complement activation in Alzheimer disease.
    McGeer PL; McGeer EG
    Trends Mol Med; 2002 Nov; 8(11):519-23. PubMed ID: 12421685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic complement inhibition: new developments.
    Emlen W; Li W; Kirschfink M
    Semin Thromb Hemost; 2010 Sep; 36(6):660-8. PubMed ID: 20865643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics.
    Mohebnasab M; Eriksson O; Persson B; Sandholm K; Mohlin C; Huber-Lang M; Keating BJ; Ekdahl KN; Nilsson B
    Front Immunol; 2019; 10():2539. PubMed ID: 31787968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel C5a regulators in inflammatory disease.
    Mizuno M; Cole DS
    Expert Opin Investig Drugs; 2005 Jul; 14(7):807-21. PubMed ID: 16022570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injury site-specific targeting of complement inhibitors for treating stroke.
    Alawieh A; Tomlinson S
    Immunol Rev; 2016 Nov; 274(1):270-280. PubMed ID: 27782326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of complement and perspectives for intervention in ischemia-reperfusion damage.
    Banz Y; Rieben R
    Ann Med; 2012 May; 44(3):205-17. PubMed ID: 21254897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation, cytokines, and adhesion molecules in children undergoing cardiac surgery with or without cardiopulmonary bypass.
    Tárnok A; Hambsch J; Emmrich F; Sack U; van Son J; Bellinghausen W; Borte M; Schneider P
    Pediatr Cardiol; 1999; 20(2):113-25. PubMed ID: 9986887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No prominent role for terminal complement activation in the early myocardial reperfusion phase following cardiac surgery.
    Kortekaas KA; van der Pol P; Lindeman JH; Baan CC; van Kooten C; Klautz RJ
    Eur J Cardiothorac Surg; 2012 May; 41(5):e117-25. PubMed ID: 22408044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights of an old defense system: structure, function, and clinical relevance of the complement system.
    Ehrnthaller C; Ignatius A; Gebhard F; Huber-Lang M
    Mol Med; 2011; 17(3-4):317-29. PubMed ID: 21046060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation in heart diseases. Role of oxidants.
    Chakraborti T; Mandal A; Mandal M; Das S; Chakraborti S
    Cell Signal; 2000 Oct; 12(9-10):607-17. PubMed ID: 11080612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic inhibition of the early phase of complement activation.
    Roos A; Ramwadhdoebé TH; Nauta AJ; Hack CE; Daha MR
    Immunobiology; 2002 Sep; 205(4-5):595-609. PubMed ID: 12396018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local renal complement activation mediates immune kidney injury by inducing endothelin-1 signalling and inflammation in trichloroethylene-sensitised mice.
    Wang G; Zhang J; Dai Y; Xu Q; Zhu Q
    Toxicol Lett; 2020 Oct; 333():130-139. PubMed ID: 32763311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.